Dr. Shammo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
645 N. Michigan Avenue
Suite 1020
Chicago, IL 60611
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 1996 - 1999
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1991 - 1995
- University of Chicago (NorthShore)Residency, Pathology-Anatomic and Clinical, 1988 - 1991
- University of Aleppo Faculty of MedicineClass of 1985
Certifications & Licensure
- IL State Medical License 1988 - 2026
- American Board of Internal Medicine Hematology
- American Board of Pathology Anatomic Pathology & Clinical Pathology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Phase 2, Open-Label, Multi-Dose Study of Panhematin in Patients With MDS Start of enrollment: 2007 May 01
- CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
- A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes Start of enrollment: 2011 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 35 citationsClinical Presentation, Diagnosis, and Prognosis of Myelodysplastic SyndromesJames M. Foran, Jamile M. Shammo
The American Journal of Medicine. 2012-07-01 - 78 citationsBaseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH RegistryHubert Schrezenmeier, Alexander Röth, David J. Araten, Yuzuru Kanakura, Loree Larratt
Annals of Hematology. 2020-05-10 - 9 citationsAuthor Correction: RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia.Jason X. Cheng, Li Chen, Yuan Li, Adam Cloe, Ming Yue
Nature Communications. 2018-06-06
Abstracts/Posters
- Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the USJamile M. Shammo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Novel Patient Reported Outcome Instrument Assessing the Symptoms of Paroxysmal Nocturnal HemoglobinuriaJamile M. Shammo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center DatabaseJamile M. Shammo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies60th American Society of Hematology Annual Meeting - 11/30/2018
Authored Content
- Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria with EculizumabOctober 2017
Press Mentions
- ASH Announces Executive Committee Election Results, New Clinical Practice Guidelines, and MoreNovember 5th, 2020
- Diagnosis of Myelodysplastic SyndromeJanuary 29th, 2020
- Repurposed Drug Gives Woman with Cancer the Gift of LifeJuly 1st, 2018
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: